COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES

• US 20090017014A1
• Filed: 07/29/2008
• Published: 01/15/2009
• Est. Priority Date: 08/29/2001
• Status: Abandoned Application

• Current Assignee: Austin L. Gurney, Iqbal Grewal, Patricia A. Valdez
• Original Assignee: Austin L. Gurney, Iqbal Grewal, Patricia A. Valdez
• Inventors: Grewal, Iqbal, Valdez, Patricia A., Gurney, Austin L.
• Application Number:
  US12/182,090
• Publication Number:
  US 20090017014A1
• Time in Patent Office: Days
• US Class Current: 424/130.100
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/02 Nasal agents, e.g. decongestants
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 5/14 of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/06 : Antianaemics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 14/47 : from mammals

Abstract

The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases.

Claims

1. An isolated polypeptide having at least 80% amino acid sequence identity to:

(a) an amino acid sequence of the polypeptide shown in FIG. 2 (SEQ ID NO;

2);

(b) an amino acid sequence of the polypeptide shown in FIG. 2 (SEQ ID NO;

2);

lacking its associated signal peptide;

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in FIG. 2 (SEQ ID NO;

2);

with its associated signal peptide;

or

(d) an amino acid sequence of an extracellular domain of the polypeptide shown in FIG. 2 (SEQ ID NO;

2);

lacking its associated signal peptide.

3. A chimeric molecule comprising a polypeptide according to claim 1 fused to a heterologous amino acid sequence.

4. The chimeric molecule of claim 3, wherein said heterologous amino acid sequence is an epitope tag sequence or an Fc region of an immunoglobulin.

5. A composition of matter comprising (a) a polypeptide of claim 1, (b) an agonist of said polypeptide, (c) an antagonist of said polypeptide, or (d) an antibody that binds to said polypeptide, in combination with a carrier.

6. The composition of matter of claim 5, wherein said carrier is a pharmaceutically acceptable carrier.

7. The composition of matter of claim 5 comprising a therapeutically effective amount of (a), (b), (c) or (d).

8. An article of manufacture, comprising:

a container;

a label on said container; and

a composition of matter comprising (a) a polypeptide of claim 1, (b) an agonist of said polypeptide, (c) an antagonist of said polypeptide, or (d) an antibody that binds to said polypeptide, contained within said container, wherein label on said container indicates that said composition of matter can be used for treating an immune related disease.

2. An isolated polypeptide having at least 80% amino acid sequence identity to an amino acid sequence encoded by the full-length coding sequence of the DNA deposited under the ATCC accession number PTA-1731.